The RAM-LM group showed a trend toward a shorter duration of BEV administration, except in one case; this was due to the early failure of front-line BEV plus oxaliplatin-based chemotherapy.
← all excerpts
Ramucirumab in second‑line advanced colorectal cancer therapy: A study on therapeutic outcomes and hepatic sinusoidal platelet aggregation.
1
—
—